SCHEMBL20914083

SCHEMBL20914083

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(S(C)(=O)=O)nn4c3=O)nc12

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNKS O95271 2/20 0.38
▸ TNKS2 Q9H2K2 2/20 0.38
▸ PARP2 Q9UGN5 1/20 0.38
▸ F2RL3 Q96RI0 2/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ DHODH Q02127 1/20 0.34
▸ DCTPP1 Q9H773 1/20 0.33
▸ TOP2A P11388 1/20 0.33
▸ PARP1 P09874 1/20 0.33
▸ KDM4E B2RXH2 3/20 0.33
▸ ALDH1A1 P00352 3/20 0.33
▸ MAPT P10636 3/20 0.33
▸ HPGD P15428 2/20 0.33
▸ HSD17B10 Q99714 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ AR P10275 1/20 0.33
▸ PTPN2 P17706 2/20 0.33
▸ PTPN1 P18031 2/20 0.33
▸ PTPN5 P54829 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20931219 0.90 TNKS (0.40) TNKSTNKS2PARP2F2RL3SMN1; SMN2
SCHEMBL20914415 0.89 TNKS (0.39) TNKSTNKS2PARP2F2RL3SMN1; SMN2
SCHEMBL20914016 0.88 TNKS (0.39) TNKSTNKS2PARP2F2RL3DHODH
SCHEMBL20914255 0.87 TNKS (0.37) TNKSTNKS2PARP2F2RL3DHODH
SCHEMBL20837249 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3DHODH
SCHEMBL20837248 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3DHODH
SCHEMBL20914077 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3SMN1; SMN2
SCHEMBL20914212 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3DHODH
SCHEMBL20819069 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3DCTPP1
SCHEMBL20914002 0.86 TNKS (0.37) TNKSTNKS2PARP2F2RL3SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 TNKS 531/4885TNKS2 932/4885PARP2 1671/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback